L3VLUP
ProSign in

PRGO · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

PRGOVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • PRGO
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterPRGOVRTX
Q3 202010 holders, $958m31 holders, $21.9bn
Q4 20208 holders, $897m30 holders, $18.4bn
Q1 20217 holders, $1.1bn31 holders, $15.4bn
Q2 20219 holders, $1.3bn30 holders, $12.7bn
Q3 20219 holders, $1.1bn35 holders, $10.1bn
Q4 20219 holders, $534m28 holders, $12.4bn
Q1 202210 holders, $637m23 holders, $16.1bn
Q2 202212 holders, $565m25 holders, $18.1bn
Q3 20229 holders, $258m22 holders, $18.4bn
Q4 20229 holders, $168m28 holders, $18.4bn
Q1 20239 holders, $183m26 holders, $21.4bn
Q2 20237 holders, $123m27 holders, $24.7bn
Q3 20237 holders, $177m33 holders, $24.3bn
Q4 20238 holders, $181m32 holders, $28.6bn
Q1 20245 holders, $124m31 holders, $29.8bn
Q2 20244 holders, $84m29 holders, $33.4bn
Q3 20244 holders, $94m27 holders, $33.5bn
Q4 20244 holders, $294m26 holders, $28.5bn
Q1 20255 holders, $454m21 holders, $35.4bn
Q2 20254 holders, $516m21 holders, $32.3bn
Q3 20255 holders, $527m22 holders, $25.9bn
Q4 20254 holders, $373m26 holders, $31.8bn
Q1 20263 holders, $136m25 holders, $31.8bn
Q2 20264 holders, $136m26 holders, $34.6bn
PRGO

Perrigo Co PLC

Holders
8
Reported value
$181m
Buyers
7
Sellers
1

Breadth +6 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
32
Reported value
$28.6bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 36 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only PRGO (4)

GAMCO Investors Inc, Holocene Advisors LP, Quantbot Technologies LP, Schonfeld Strategic Advisors LLC

Only VRTX (28)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Farallon Capital Management LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Marshall Wace LLP, Maverick Capital Ltd, MFS Investment Management, Millennium Management LLC, PDT Partners LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, and 3 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →